Literature DB >> 11309270

A gene hypermethylation profile of human cancer.

M Esteller1, P G Corn, S B Baylin, J G Herman.   

Abstract

We are in an era where the potential exists for deriving comprehensive profiles of DNA alterations characterizing each form of human cancer. Such profiles would provide invaluable insight into mechanisms underlying the evolution of each tumor type and will provide molecular markers, which could radically improve cancer detection. To date, no one type of DNA change has been defined which accomplishes this purpose. Herein, by using a candidate gene approach, we show that one category of DNA alteration, aberrant methylation of gene promoter regions, can enormously contribute to the above goals. We have now analyzed a series of promoter hypermethylation changes in 12 genes (p16(INK4a), p15(INK4b), p14(ARF), p73, APC,(5) BRCA1, hMLH1, GSTP1, MGMT, CDH1, TIMP3, and DAPK), each rigorously characterized for association with abnormal gene silencing in cancer, in DNA from over 600 primary tumor samples representing 15 major tumor types. The genes play known important roles in processes encompassing tumor suppression, cell cycle regulation, apoptosis, DNA repair, and metastastic potential. A unique profile of promoter hypermethylation exists for each human cancer in which some gene changes are shared and others are cancer-type specific. The hypermethylation of the genes occurs independently to the extent that a panel of three to four markers defines an abnormality in 70-90% of each cancer type. Our results provide an unusual view of the pervasiveness of DNA alterations, in this case an epigenetic change, in human cancer and a powerful set of markers to outline the disruption of critical pathways in tumorigenesis and for derivation of sensitive molecular detection strategies for virtually every human tumor type.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309270

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  543 in total

1.  Enzymatic regional methylation assay: a novel method to quantify regional CpG methylation density.

Authors:  Oliver Galm; Michael R Rountree; Kurtis E Bachman; Kam-Wing Jair; Stephen B Baylin; James G Herman
Journal:  Genome Res       Date:  2002-01       Impact factor: 9.043

2.  Left and right sided large bowel cancer.

Authors:  Susan Richman; Julian Adlard
Journal:  BMJ       Date:  2002-04-20

3.  Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry.

Authors:  Jörg Tost; Philipp Schatz; Matthias Schuster; Kurt Berlin; Ivo Glynne Gut
Journal:  Nucleic Acids Res       Date:  2003-05-01       Impact factor: 16.971

4.  DNA methylation biomarkers for lung cancer.

Authors:  Tibor A Rauch; Zunde Wang; Xiwei Wu; Kemp H Kernstine; Arthur D Riggs; Gerd P Pfeifer
Journal:  Tumour Biol       Date:  2011-12-06

5.  Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia.

Authors:  Takayoshi Waki; Gen Tamura; Takashi Tsuchiya; Kiyoshi Sato; Satoshi Nishizuka; Teiichi Motoyama
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

6.  HPLC method development, validation, and impurity characterization of a potent antitumor nucleoside, T-dCyd (NSC 764276).

Authors:  Mingtao Liu; Jennie Wang; Paul Liu
Journal:  J Pharm Biomed Anal       Date:  2016-09-09       Impact factor: 3.935

Review 7.  Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies.

Authors:  Oliver Galm; Manel Esteller
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

8.  Effects of DNA methylation on expression of tumor suppressor genes and proto-oncogene in human colon cancer cell lines.

Authors:  Jing-Yuan Fang; Juan Lu; Ying-Xuan Chen; Li Yang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

Review 9.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

10.  Predicting aberrant CpG island methylation.

Authors:  F A Feltus; E K Lee; J F Costello; C Plass; P M Vertino
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.